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Sleeping sickness is an infectious disease that is caused by the protozoan parasite For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity 24 against bloodstream forms of T. brucei. The concentration of the drug required to reduce the 25 growth rate of the parasites by 50% was 29.1 μM and to kill all trypanosomes was 125 μM.
26
Importantly, temozolomide did not affect the growth of human HL-60 cells up to a 27 concentration of 300 μM. Cell cycle analysis revealed that temozolomide induced DNA 28 damage and subsequent cell cycle arrest in trypanosomes exposed to the compound. As drug 29 combination regimes often achieve greater therapeutic efficacy than monotherapies, the 30 interactions of temozolomide with the trypanocides eflornithine and melarsoprol, 31 respectively, was determined. Both combinations were found to produce an additive effect. In 
Introduction

45
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a tropical 46 neglected disease occurring in rural areas of sub-Saharan Africa (Steverding, 2008) . The cytometer. Debris and cell fragments were excluded from analysis through gating on forward
128
and site scatter properties, and 50,000 cells were analysed. trypanosomes/ml. The assay was evaluated and GI50 values calculated as described above.
141
The fractional inhibitory concentration (FIC) at the GI50 value was calculated as FIC = The trypanocidal and cytotoxic activity of the anti-glioblastoma drug temozolomide was 151 evaluated with bloodstream forms of T. brucei and human myeloid leukaemia HL-60 cells.
152
Temozolomide showed a concentration-dependent inhibitory effect on the growth of T. 
204
The indifferent interaction was also confirmed by plotting the individual FIC values in 205 isobolograms (Fig. 4) , where all points were close to the additivity line.
206
Temozolomide is an oral alkylating prodrug that is 100% bioavailable and able to cross 
212
These pharmacological properties make the drug an interesting agent for treating the of temozolomide in combination with eflornithine or melarsoprol.
231
As for many anti-cancer drugs, temozolomide causes side effects but is usually well 
